Sociodemographic and clinical characteristics of people with oldest older age bipolar disorder in a global sample: Results from the global aging and geriatric experiments in bipolar disorder project

Nenhuma Miniatura disponível
Citações na Scopus
0
Tipo de produção
article
Data de publicação
2024
DOI
Scopus
Web of Science
Dimensions
Título da Revista
ISSN da Revista
Título do Volume
Editora
WILEY
Autores
CHEN, Peijun
SAJATOVIC, Martha
BRIGGS, Farren B. S.
MULSANT, Benoit
DOLS, Annemiek A.
GILDENGERS, Ariel
YALA, Joy
BEUNDERS, Alexandra J. M.
BLUMBERG, Hilary P.
REJ, Soham
Citação
INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY, v.39, n.2, article ID e6073, 11p, 2024
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Objects: Studies of older age bipolar disorder (OABD) have mostly focused on ""younger old"" individuals. Little is known about the oldest OABD (OOABD) individuals aged >= 70 years old. The Global Aging and Geriatric Experiments in Bipolar Disorder (GAGE-BD) project provides an opportunity to evaluate the OOABD group to understand their characteristics compared to younger groups. Methods: We conducted cross-sectional analyses of the GAGE-BD database, an integrated, harmonized dataset from 19 international studies. We compared the sociodemographic and clinical characteristics of those aged <50 (YABD, n = 184), 50-69 (OABD, n = 881), and >= 70 (OOABD, n = 304). To standardize the comparisons between age categories and all characteristics, we used multinomial logistic regression models with age category as the dependent variable, with each characteristic as the independent variable, and clustering of standard errors to account for the correlation between observations from each of the studies. Results: OOABD and OABD had lower severity of manic symptoms (Mean YMRS = 3.3, 3.8 respectively) than YABD (YMRS = 7.6), and lower depressive symptoms (% of absent = 65.4%, and 59.5% respectively) than YABD (18.3%). OOABD and OABD had higher physical burden than YABD, especially in the cardiovascular domain (prevalence = 65% in OOABD, 41% in OABD and 17% in YABD); OOABD had the highest prevalence (56%) in the musculoskeletal domain (significantly differed from 39% in OABD and 31% in YABD which didn't differ from each other). Overall, OOABD had significant cumulative physical burden in numbers of domains (mean = 4) compared to both OABD (mean = 2) and YABD (mean = 1). OOABD had the lowest rates of suicidal thoughts (10%), which significantly differed from YABD (26%) though didn't differ from OABD (21%). Functional status was higher in both OOABD (GAF = 63) and OABD (GAF = 64), though only OABD had significantly higher function than YABD (GAF = 59). Conclusions: OOABD have unique features, suggesting that (1) OOABD individuals may be easier to manage psychiatrically, but require more attention to comorbid physical conditions; (2) OOABD is a survivor cohort associated with resilience despite high medical burden, warranting both qualitative and quantitative methods to better understand how to advance clinical care and ways to age successfully with BD.
Palavras-chave
aging, demographic and clinical characteristics, depressive symptoms, manic symptoms, oldest older age bipolar disorder, physical comorbidity
URI
https://observatorio.fm.usp.br/handle/OPI/59000
Referências
  1. Aas IHM, 2010, ANN GEN PSYCHIATR, V9, DOI 10.1186/1744-859X-9-20
  2. Ahearn E., 2021, Chapter 29-Older-Age Bipolar Disorder, Editor(s): Joao Quevedo, Andre Ferrer Carvalho, Eduard Vieta, Neurobiology of Bipolar Disorder, P335
  3. Aizenstein HJ, 2016, BMC MED, V14, DOI 10.1186/s12916-016-0720-5
  4. Beunders AJM, 2023, CURR OPIN PSYCHIATR, V36, P397, DOI 10.1097/YCO.0000000000000883
  5. Carvalho AF, 2020, NEW ENGL J MED, V383, P58, DOI 10.1056/NEJMra1906193
  6. Chan JKN, 2022, BRIT J PSYCHIAT, V221, P567, DOI 10.1192/bjp.2022.19
  7. Chaudhry S, 2005, MED CARE, V43, P607, DOI 10.1097/01.mlr.0000163658.65008.ec
  8. Chen Peijun, 2022, Psychopharmacol Bull, V52, P8
  9. Chen PJ, 2017, CURR PSYCHIAT REP, V19, DOI 10.1007/s11920-017-0804-8
  10. Crump C, 2013, JAMA PSYCHIAT, V70, P931, DOI 10.1001/jamapsychiatry.2013.1394
  11. Depp CA, 2004, BIPOLAR DISORD, V6, P343, DOI 10.1111/j.1399-5618.2004.00139.x
  12. Fares-Otero NE, 2022, EUR NEUROPSYCHOPHARM, V60, P22, DOI 10.1016/j.euroneuro.2022.04.002
  13. Fenn HH, 2005, J AFFECT DISORDERS, V86, P47, DOI 10.1016/j.jad.2004.12.006
  14. Fico G, 2022, EUR NEUROPSYCHOPHARM, V60, P55, DOI 10.1016/j.euroneuro.2022.05.004
  15. Forester BP, 2015, AM J GERIAT PSYCHIAT, V23, P977, DOI 10.1016/j.jagp.2015.01.001
  16. Forlenza OV, 2022, ACTA PSYCHIAT SCAND, V146, P442, DOI 10.1111/acps.13474
  17. Fornaro M, 2016, J AFFECT DISORDERS, V195, P105, DOI 10.1016/j.jad.2016.01.040
  18. Fries GR, 2020, NEUROSCI BIOBEHAV R, V112, P107, DOI 10.1016/j.neubiorev.2020.01.035
  19. Gildengers AG, 2004, AM J PSYCHIAT, V161, P736, DOI 10.1176/appi.ajp.161.4.736
  20. HAMILTON M, 1960, J NEUROL NEUROSUR PS, V23, P56, DOI 10.1136/jnnp.23.1.56
  21. Ilzarbe L, 2023, EUR NEUROPSYCHOPHARM, V71, P6, DOI 10.1016/j.euroneuro.2023.03.001
  22. Iturralde Esti, 2022, NEJM Catal Innov Care Deliv, V3, DOI 10.1056/CAT.21.0417
  23. Jones BDM, 2023, PSYCHOL MED, V53, P6316, DOI 10.1017/S0033291722003622
  24. Kessing LV, 2015, J AFFECT DISORDERS, V180, P142, DOI 10.1016/j.jad.2015.03.027
  25. Kilbourne AM, 2017, J CLIN PSYCHIAT, V78, P129, DOI 10.4088/JCP.15m10301
  26. Lala SV, 2012, J GERIATR PSYCH NEUR, V25, P20, DOI 10.1177/0891988712436683
  27. Lavin P, 2022, INT J GERIATR PSYCH, V37, DOI 10.1002/gps.5833
  28. LINN BS, 1968, J AM GERIATR SOC, V16, P622, DOI 10.1111/j.1532-5415.1968.tb02103.x
  29. MILLER MD, 1992, PSYCHIAT RES, V41, P237, DOI 10.1016/0165-1781(92)90005-N
  30. Montejo L, 2022, BIPOLAR DISORD, V24, P115, DOI 10.1111/bdi.13175
  31. MONTGOMERY SA, 1979, BRIT J PSYCHIAT, V134, P382, DOI 10.1192/bjp.134.4.382
  32. Orhan M, 2022, J AFFECT DISORDERS, V314, P44, DOI 10.1016/j.jad.2022.06.074
  33. RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306
  34. Rhee TG, 2020, AM J PSYCHIAT, V177, P706, DOI 10.1176/appi.ajp.2020.19091000
  35. Rise IV, 2016, NEUROPSYCH DIS TREAT, V12, P1203, DOI 10.2147/NDT.S100843
  36. Rizzo LB, 2014, NEUROSCI BIOBEHAV R, V42, P157, DOI 10.1016/j.neubiorev.2014.02.004
  37. Sajatovic M., 2019, Bipolar Disord, P1
  38. Sajatovic M, 2022, BIPOLAR DISORD, V24, P195, DOI 10.1111/bdi.13119
  39. Sajatovic M, 2015, BIPOLAR DISORD, V17, P689, DOI 10.1111/bdi.12331
  40. Sajatovic M, 2013, NEUROPSYCHIATRY-LOND, V3, P621, DOI 10.2217/npy.13.78
  41. Samamé C, 2013, BIPOLAR DISORD, V15, P633, DOI 10.1111/bdi.12077
  42. Schürhoff F, 2000, J AFFECT DISORDERS, V58, P215, DOI 10.1016/S0165-0327(99)00111-1
  43. Seedat S, 2009, ARCH GEN PSYCHIAT, V66, P785, DOI 10.1001/archgenpsychiatry.2009.36
  44. Sepede G, 2020, PROG NEURO-PSYCHOPH, V98, DOI 10.1016/j.pnpbp.2019.109817
  45. Sheeran T, 2012, BIPOLAR DISORD, V14, P756, DOI 10.1111/bdi.12008
  46. StataCorp, 2009, STAT STAT SOFTW REL
  47. Thesing CS, 2015, J AFFECT DISORDERS, V184, P249, DOI 10.1016/j.jad.2015.05.066
  48. Thornicroft G, 2007, INT REV PSYCHIATR, V19, P113, DOI 10.1080/09540260701278937
  49. TOMBAUGH TN, 1992, J AM GERIATR SOC, V40, P922, DOI 10.1111/j.1532-5415.1992.tb01992.x
  50. Tsai SY, 2007, BIPOLAR DISORD, V9, P868, DOI 10.1111/j.1399-5618.2007.00498.x
  51. Wan H., 2016, U.S. Census Bureau, International Population Reports, P95/16-1
  52. YOUNG RC, 1978, BRIT J PSYCHIAT, V133, P429, DOI 10.1192/bjp.133.5.429

Coleções
Artigos e Materiais de Revistas Científicas - FM/MPS